Jeuveau vs Xeomin: Complete Comparison Guide

Both Jeuveau and Xeomin use botulinum toxin type A to smooth wrinkles, but they differ in formulation, FDA approvals, onset speed, and protein content.

Find providers near you
Jeuveau vs Xeomin comparison guide hero image

Jeuveau vs Xeomin

Both Jeuveau and Xeomin are FDA-approved neurotoxins that temporarily relax facial muscles to reduce wrinkles. The main differences include formulation (Jeuveau uses Hi-Pure technology with proteins, Xeomin is protein-free), FDA approvals (Xeomin has broader approvals for multiple facial areas and medical conditions, Jeuveau is approved only for glabellar lines), onset (Jeuveau 2-3 days, Xeomin 3-4 days), and cost (Jeuveau $8-$16/unit, Xeomin $10-$15/unit).

Key similarities:

  • Both contain botulinum toxin type A
  • Both last approximately 3-4 months
  • Both work by blocking nerve signals to muscles
  • Both are injected using similar techniques
  • Both have comparable safety profiles

Key differences:

  • Formulation: Jeuveau contains complexing proteins, Xeomin is protein-free ("naked injectable")
  • FDA approvals: Xeomin approved for glabellar lines, forehead lines, and crow's feet plus medical uses; Jeuveau approved only for glabellar lines
  • Onset: Jeuveau typically 2-3 days, Xeomin 3-4 days
  • Manufacturing: Jeuveau uses Hi-Pure vacuum-drying, Xeomin removes all complexing proteins
  • Cost: Jeuveau often slightly less expensive ($8-$16 vs $10-$15 per unit)

Understanding the Difference Between Jeuveau and Xeomin

The formulation and development approach create distinct characteristics.

Jeuveau: Modern Cosmetic-Focused Formulation

What is Jeuveau explains that this neurotoxin (prabotulinumtoxinA-xvfs) was developed by Evolus specifically for aesthetic use and FDA-approved in 2019. Jeuveau uses Hi-Pure technology, a proprietary vacuum-drying manufacturing process that produces smaller, more uniform protein complexes surrounding the botulinum toxin.

Jeuveau characteristics:

  • Active ingredient: PrabotulinumtoxinA-xvfs
  • Manufactured using Hi-Pure vacuum-drying technology
  • Contains complexing proteins (smaller and more uniform than traditional formulations)
  • Developed exclusively for cosmetic purposes
  • FDA-approved February 2019 for glabellar lines
  • Marketed as "Newtox" targeting younger demographic
  • Stored frozen or refrigerated before reconstitution

Xeomin: Pure Protein-Free Formulation

Xeomin (incobotulinumtoxinA) was developed by Merz Pharmaceuticals and FDA-approved in 2010 for therapeutic uses, with cosmetic approvals added over time. Xeomin is unique for being completely free of complexing proteins, earning it the nickname "naked injectable."

Xeomin characteristics:

  • Active ingredient: IncobotulinumtoxinA
  • Manufactured without any accessory or complexing proteins
  • Pure 150-kDa botulinum toxin molecule only
  • Developed for both medical and cosmetic applications
  • FDA-approved 2010 initially, with cosmetic approvals expanded through 2024
  • Can be stored at room temperature before reconstitution (unique advantage)
  • Lower theoretical risk of antibody formation due to protein-free formulation

Manufacturing Process Differences

The manufacturing differences influence product characteristics and potentially patient response.

Jeuveau's Hi-Pure process:

  • Vacuum-drying technology (vs traditional freeze-drying)
  • Creates smaller, more uniform protein complexes
  • Results in 900 kDa molecular weight formulation
  • Achieves 95%+ purity
  • May contribute to faster onset for some patients

Xeomin's purification process:

  • Removes all complexing proteins entirely
  • Only the active 150-kDa neurotoxin remains
  • Potentially reduces risk of developing resistance over time
  • Stable at room temperature, simplifying storage
  • May be better for patients with previous neurotoxin resistance

Jeuveau vs Xeomin: FDA Approvals and Uses

According to the FDA, approval differences significantly impact how providers can use these products.

Jeuveau FDA Approvals

Jeuveau has limited FDA approvals focused exclusively on cosmetic use.

FDA-approved use:

  • Moderate to severe glabellar lines (frown lines between eyebrows)

Common off-label cosmetic uses:

  • Forehead lines (horizontal wrinkles)
  • Crow's feet (lines around eyes)
  • Bunny lines (nose wrinkles)
  • Brow lift
  • Masseter reduction (jaw slimming)

No medical indications: Jeuveau has no FDA approvals for medical conditions, distinguishing it from other neurotoxins.

Xeomin FDA Approvals

Xeomin has broader FDA approvals for both cosmetic and medical applications.

FDA-approved cosmetic uses:

  • Moderate to severe glabellar lines (frown lines)
  • Forehead lines (horizontal wrinkles)
  • Crow's feet (periorbital lines)

FDA-approved medical uses:

  • Cervical dystonia (neck muscle spasms)
  • Blepharospasm (eyelid twitching)
  • Upper limb spasticity
  • Chronic sialorrhea (excessive drooling)

Common off-label cosmetic uses:

  • Bunny lines
  • Lip lines
  • Gummy smile correction
  • Platysmal bands (neck lines)

Treatment Versatility

Xeomin's broader FDA approvals make it more versatile for providers who treat both cosmetic and medical concerns. Jeuveau's cosmetic-only positioning appeals to practices focused exclusively on aesthetic treatments.

Onset and Duration: How Long Results Last

Timing differences matter for scheduling and planning.

Jeuveau Onset and Duration

Jeuveau typically shows faster initial results than Xeomin.

Timeline:

  • Days 1-2: Binding to nerve receptors (no visible changes)
  • Days 2-3: Initial visible improvements (30-50% result)
  • Days 3-5: Noticeable smoothing (50-70% result)
  • Days 10-14: Full effects (100% maximum muscle relaxation)
  • Months 1-3: Peak results stable period
  • Months 3-4: Gradual return of muscle function

Duration factors:

  • Average duration: 3-4 months
  • Some patients report: 4-5 months with regular treatments
  • Individual variation based on metabolism, muscle strength, and lifestyle
  • How long does Jeuveau last details factors affecting longevity

Xeomin Onset and Duration

Xeomin has slightly slower onset but comparable duration.

Timeline:

  • Days 1-3: Binding phase (minimal visible changes)
  • Days 3-4: Initial improvements (20-40% result)
  • Days 5-7: Progressive smoothing (50-70% result)
  • Days 10-14: Full effects (100% maximum relaxation)
  • Months 1-3: Stable peak results
  • Months 3-4: Gradual fading

Duration factors:

  • Average duration: 3-4 months
  • Comparable longevity to Jeuveau in clinical studies
  • Same individual factors affect duration (metabolism, muscle activity)
  • Regular treatments may extend duration slightly over time

Clinical Significance of Onset Differences

The 1-2 day difference in onset is clinically minor but may matter for event planning. If you need results for a specific occasion, Jeuveau's faster onset (often visible by day 2-3) provides a slight advantage over Xeomin (day 3-4). For routine maintenance, this difference is negligible.

Cost Comparison: Jeuveau vs Xeomin Pricing

Understanding pricing helps with budgeting and value assessment.

Per-Unit Cost Comparison

Both products are priced by the unit, with Jeuveau typically slightly less expensive.

Jeuveau pricing:

  • National average: $8-$16 per unit
  • Most common range: $10-$14 per unit
  • Positioned as more affordable option
  • Evolus rewards program available

Xeomin pricing:

  • National average: $10-$15 per unit
  • Most common range: $11-$14 per unit
  • Mid-range pricing among neurotoxins
  • Comparable to Botox in many markets

Cost comparison by region:

  • Major metros: Jeuveau $12-$16, Xeomin $13-$15
  • Suburban areas: Jeuveau $10-$14, Xeomin $11-$14
  • Rural areas: Jeuveau $8-$12, Xeomin $10-$13

Unit Requirements and Total Cost

Both products use approximately 1:1 unit conversion, so unit requirements are similar for equivalent treatments. Jeuveau cost provides detailed area-specific pricing.

Typical units by area:

Glabellar lines (both products):

  • Standard dose: 20 units
  • Jeuveau cost: $160-$320 (at $8-$16/unit)
  • Xeomin cost: $200-$300 (at $10-$15/unit)

Forehead lines:

  • Standard dose: 15-20 units
  • Jeuveau cost: $120-$320
  • Xeomin cost: $150-$300

Crow's feet (both sides):

  • Standard dose: 24 units
  • Jeuveau cost: $192-$384
  • Xeomin cost: $240-$360

Full upper face:

  • Standard dose: 60-64 units
  • Jeuveau cost: $480-$1,024
  • Xeomin cost: $600-$960

Annual Cost Considerations

With both lasting 3-4 months, annual costs depend on treatment frequency.

Annual cost for glabellar lines (3.5 treatments/year at average pricing):

  • Jeuveau at $12/unit: $240 × 3.5 = $840 annually
  • Xeomin at $13/unit: $260 × 3.5 = $910 annually
  • Potential annual savings with Jeuveau: $70

The cost difference is modest but can add up over years of regular treatment.

Results and Effectiveness

Both products deliver comparable wrinkle reduction.

Clinical Trial Results

Published studies show similar efficacy for both neurotoxins.

Jeuveau clinical data:

  • Phase III trials (EV-001 and EV-002): 67.5-70.4% of patients showed visible improvement in frown lines at day 30
  • Non-inferiority studies: Comparable efficacy to Botox (and by extension, similar neurotoxins)
  • High patient satisfaction rates: 91% on RealSelf reviews
  • Consistent results across diverse patient populations

Xeomin clinical data:

  • Multiple studies demonstrate efficacy for glabellar lines, forehead lines, and crow's feet
  • Non-inferiority to Botox in head-to-head trials
  • High patient satisfaction: 96% on RealSelf reviews
  • Extensive safety data from both cosmetic and medical uses

Real-World Results

Patient experiences confirm similar effectiveness.

What to expect with Jeuveau:

  • Smooth, natural-looking results
  • Preservation of facial expression when properly dosed
  • Consistent wrinkle reduction across treatment areas
  • Faster visible onset (days 2-3) appreciated by many patients
  • Even spread across treatment area

What to expect with Xeomin:

  • Natural, subtle wrinkle smoothing
  • Maintained facial mobility
  • Reliable, predictable results
  • Slightly slower onset but equally effective final results
  • May feel more comfortable during injection (some patients report)

Comparing Natural Appearance

Both products can achieve natural-looking results when administered by experienced injectors. The "natural vs frozen" outcome depends far more on injector technique, dosing accuracy, and placement than on product choice. Neither Jeuveau nor Xeomin inherently produces more natural or more frozen results.

Jeuveau or Xeomin: Who Should Choose Which

Ideal candidates differ based on specific circumstances.

Best Candidates for Jeuveau

Jeuveau may be the better choice if you fit these criteria.

Ideal for:

  • First-time neurotoxin users seeking an affordable entry point
  • Younger patients (20s-30s) using preventive treatments
  • Those wanting faster visible results (event planning)
  • Patients focused exclusively on cosmetic goals
  • Budget-conscious individuals seeking quality at lower cost
  • People who prefer newer, modern formulations

Particularly good for:

  • Glabellar line treatment (FDA-approved indication)
  • Preventive "baby Botox" approaches
  • Patients without medical neurotoxin needs
  • Those who respond well to protein-containing formulations
  • Individuals enrolled in Evolus rewards programs

Best Candidates for Xeomin

Xeomin may be preferable in these situations.

Ideal for:

  • Patients with history of reduced response to other neurotoxins (potential antibody resistance)
  • Those treating multiple facial areas beyond glabellar lines
  • Patients needing both cosmetic and medical neurotoxin treatments
  • People with sensitive skin or protein sensitivities
  • Those who prefer the most purified formulation
  • Patients with storage/refrigeration concerns (providers)

Particularly good for:

  • Long-term neurotoxin users experiencing reduced effectiveness
  • Treatment of forehead lines and crow's feet (FDA-approved)
  • Patients with medical conditions like cervical dystonia or blepharospasm
  • Those prioritizing lowest antibody formation risk
  • Comprehensive facial rejuvenation across multiple areas

When Either Works Equally Well

For many patients, either product delivers excellent results.

Scenarios where choice matters less:

  • Standard glabellar line treatment in healthy adults
  • First or second neurotoxin treatment (no resistance concerns)
  • Patients with no protein sensitivities
  • When treated by experienced injector familiar with both products
  • Budget differences aren't significant concern

In these cases, provider preference, pricing, and availability may be deciding factors.

Safety and Side Effects

Both neurotoxins have well-established safety profiles.

Common Side Effects

Expected mild, temporary reactions are similar for both products.

Typical side effects (both products):

  • Injection site reactions: redness, swelling, tenderness, bruising
  • Headache (mild, temporary)
  • Flu-like symptoms (rare)
  • Temporary eyelid heaviness (if product migrates)

Duration: Most side effects resolve within 24-48 hours, with bruising potentially lasting up to one week.

Rare Serious Risks

As with all botulinum toxin products, serious risks exist but are rare when treatments are performed correctly.

Potential serious complications (both products):

  • Difficulty breathing or swallowing
  • Severe muscle weakness
  • Vision problems
  • Allergic reactions (anaphylaxis extremely rare)
  • Unintended spread to distant muscles

These serious effects are extremely uncommon with properly administered cosmetic doses by qualified providers.

Antibody Formation Risk

Theoretical differences exist in antibody development potential.

Xeomin advantage:

  • Protein-free formulation theoretically reduces antibody formation risk
  • May be better option for long-term users (10+ years of regular treatments)
  • Potentially lower immunogenicity
  • Clinical significance of this advantage remains debated

Jeuveau considerations:

  • Contains proteins but uses smaller, more uniform protein complexes
  • Hi-Pure technology may reduce antibody risk compared to traditional formulations
  • Limited long-term data (newer product approved 2019)
  • Most patients won't develop antibodies regardless of product

For most people, antibody formation is not a practical concern with either product.

Provider Selection and Treatment Process

Choosing a qualified injector matters more than product selection.

Finding Qualified Providers

Look for these credentials and characteristics.

Essential qualifications:

  • Board certification in dermatology, plastic surgery, or related field
  • Extensive neurotoxin injection experience (minimum 2-3 years)
  • Proper medical licensing and facility oversight
  • Portfolio of before/after photos demonstrating natural results
  • Detailed consultation process
  • Transparent pricing and treatment planning

Questions to ask providers:

  • How much experience do you have with Jeuveau and Xeomin?
  • Which product do you recommend for my specific concerns and why?
  • How many units do you typically use for [your treatment area]?
  • What's your approach to achieving natural-looking results?
  • What happens if I'm not satisfied with results?

Treatment Process

The injection process is identical regardless of product choice.

Typical appointment timeline:

Consultation (10-15 minutes):

  • Facial assessment and muscle analysis
  • Medical history review
  • Treatment area determination
  • Unit calculation and cost estimate
  • Before photos

Injection procedure (10-20 minutes):

  • Face cleansing and marking injection sites
  • Ice or numbing cream application (optional)
  • Precise injections into targeted muscles
  • Post-treatment assessment

Aftercare instructions (5 minutes):

  • First 4 hours: Stay upright, avoid touching treated areas
  • First 24 hours: No exercise, no lying flat, no alcohol
  • Following days: Normal activities resume, protect from sun

Follow-up:

  • 2-week check-in for results assessment
  • Touch-up if needed (additional cost may apply)
  • Schedule next maintenance treatment

Switching Between Products

Many patients try different neurotoxins or switch over time.

Can You Switch from Xeomin to Jeuveau or Vice Versa?

Yes, switching between neurotoxins is safe and common. Because both use botulinum toxin type A, transitioning doesn't require special protocols beyond waiting for previous treatment to wear off completely.

Switching considerations:

  • Wait until previous product has fully worn off (3-4 months)
  • Expect approximately 1:1 unit conversion
  • Results should be comparable if properly dosed
  • Some patients respond slightly better to one formulation
  • Trial and error helps determine which works best for you

Why Patients Switch

Common reasons to switch from Xeomin to Jeuveau:

  • Cost savings (if Jeuveau priced lower in your area)
  • Desire for faster onset
  • Interest in trying newer formulation
  • Provider recommendation based on response patterns

Common reasons to switch from Jeuveau to Xeomin:

  • Reduced effectiveness over time (antibody concerns)
  • Need for medical applications (Jeuveau has no medical FDA approvals)
  • Treatment of multiple facial areas (Xeomin has broader cosmetic approvals)
  • Protein sensitivity concerns

Comparing Jeuveau and Xeomin to Other Neurotoxins

Understanding the broader competitive landscape provides context.

Jeuveau vs Botox vs Xeomin

Jeuveau vs Botox shows these three products have distinct positioning.

Quick comparison:

  • Botox: Most established (FDA-approved 2002), broadest applications, highest brand recognition, $10-$20/unit
  • Jeuveau: Newest cosmetic-only option (2019), fastest onset, most affordable, $8-$16/unit
  • Xeomin: Middle ground (2010), protein-free "naked" formulation, medical and cosmetic uses, $10-$15/unit

Jeuveau vs Dysport vs Xeomin

Jeuveau vs Dysport adds another comparison point.

Key differentiators:

  • Dysport: Fastest onset (2-3 days), wider spread pattern, often needs more units, $4-$8/unit
  • Jeuveau: Moderate onset (2-3 days), precise spread, standard dosing, $8-$16/unit
  • Xeomin: Slower onset (3-4 days), precise spread, protein-free, $10-$15/unit

FAQs: Jeuveau vs Xeomin

What is the difference between Jeuveau and Xeomin? +
The main differences are formulation, FDA approvals, and onset speed. Jeuveau (prabotulinumtoxinA-xvfs) contains complexing proteins manufactured using Hi-Pure vacuum-drying technology and is FDA-approved only for glabellar lines, with onset typically 2-3 days. Xeomin (incobotulinumtoxinA) is completely protein-free ("naked injectable"), FDA-approved for glabellar lines, forehead lines, crow's feet plus multiple medical conditions, with onset 3-4 days. Both use botulinum toxin type A, last 3-4 months, and work through the same mechanism of temporarily blocking nerve signals to muscles. Cost is similar, with Jeuveau often $8-$16 per unit versus Xeomin $10-$15 per unit.
Is Jeuveau better than Xeomin? +
Neither is objectively "better"—they excel in different scenarios. Jeuveau may be better if you want faster onset (2-3 days vs 3-4), lower cost (often $2-4 less per unit), or are a first-time user seeking an affordable option. Xeomin may be better if you've experienced reduced effectiveness with other neurotoxins (protein-free formulation reduces antibody risk), need treatment for multiple facial areas (broader FDA approvals), or require both cosmetic and medical neurotoxin applications. Clinical studies show both achieve approximately 70% patient improvement for glabellar lines at 30 days. The "better" choice depends on your specific goals, budget, treatment history, and provider recommendation based on facial assessment.
Does Xeomin last longer than Jeuveau? +
No, both products last approximately 3-4 months on average. Clinical data and real-world experience show comparable duration for Jeuveau and Xeomin when properly dosed. Some individual patients report slight differences (4-5 months for either product with regular treatments), but these variations are due to individual factors like metabolism, muscle strength, lifestyle, and treatment consistency rather than inherent product differences. Duration depends more on your unique physiology than product choice. With regular maintenance every 3-4 months, both products may train muscles to stay relaxed slightly longer over time, potentially extending results, but neither consistently outlasts the other in clinical practice.
Is Jeuveau cheaper than Xeomin? +
Yes, Jeuveau is typically $1-4 less expensive per unit than Xeomin, though pricing varies by provider and region. Jeuveau averages $8-$16 per unit (most commonly $10-$14), while Xeomin averages $10-$15 per unit (most commonly $11-$14). For standard glabellar treatment using 20 units, this translates to $160-$320 for Jeuveau versus $200-$300 for Xeomin, saving $20-$40 per session. With quarterly treatments (3.5 times annually), you might save $70-$140 per year choosing Jeuveau. However, the cost difference is modest, and other factors like provider expertise, FDA approval breadth, and your individual response may outweigh small price differences when selecting between these products.
Which looks more natural, Jeuveau or Xeomin? +
Both products can achieve equally natural-looking results when properly administered—the outcome depends far more on injector skill, dosing accuracy, and placement than product choice. Neither Jeuveau nor Xeomin inherently produces more natural or more "frozen" results. Natural appearance comes from conservative dosing that preserves some muscle movement while reducing wrinkles, precise injection technique targeting only wrinkle-causing muscles, and experienced injector understanding of facial anatomy. Some patients subjectively prefer results from one product over another due to subtle differences in how their individual muscles respond, but controlled studies show comparable aesthetic outcomes. The key to natural results is choosing a highly skilled, experienced injector rather than focusing on product brand.
Who is a good candidate for Jeuveau vs Xeomin? +
Good Jeuveau candidates include first-time neurotoxin users seeking affordable entry point, younger patients (20s-30s) using preventive treatments, those wanting faster visible results for events (2-3 day onset), and budget-conscious individuals focused exclusively on cosmetic goals. Good Xeomin candidates include patients experiencing reduced response to other neurotoxins (protein-free formulation may help), those needing treatment for multiple facial areas beyond glabellar lines (broader FDA approvals), people requiring both cosmetic and medical neurotoxin treatments, and long-term users (10+ years) concerned about antibody formation. Many patients are excellent candidates for either product—in these cases, provider expertise and recommendation, pricing, and individual trial may determine the best choice.